Last reviewed · How we verify
BNO 1016
BNO 1016 is a herbal combination product that modulates immune and inflammatory responses to support respiratory health.
BNO 1016 is a herbal combination product that modulates immune and inflammatory responses to support respiratory health. Used for Acute bronchitis with productive cough, Chronic obstructive pulmonary disease (COPD) exacerbations.
At a glance
| Generic name | BNO 1016 |
|---|---|
| Also known as | herbal plant extract,, sinupret extract mite, Sinupret extract |
| Sponsor | Bionorica SE |
| Drug class | Herbal combination / Phytotherapeutic agent |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | Phase 3 |
Mechanism of action
BNO 1016 is a standardized extract combination from Bionorica containing multiple plant-derived compounds that work synergistically to reduce airway inflammation and support mucociliary clearance. The formulation targets multiple pathways involved in respiratory inflammation and immune regulation, making it suitable for conditions characterized by impaired airway function and excessive mucus production.
Approved indications
- Acute bronchitis with productive cough
- Chronic obstructive pulmonary disease (COPD) exacerbations
Common side effects
- Gastrointestinal upset
- Nausea
- Allergic reactions (rare)
Key clinical trials
- Efficacy and Safety of Two Dosages of a Herbal Medicinal Product (Dry Extract BNO 1016) in Chronic Rhinosinusitis (PHASE3)
- Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNO 1016 CI brief — competitive landscape report
- BNO 1016 updates RSS · CI watch RSS
- Bionorica SE portfolio CI